

# Use of chromogenic Factor VIII activity determination in Haemophilia A plasma of patients under emicizumab treatment

M. Unterberger, L. Wagner, N. B. Binder Technoclone Herstellung von Diagnostika und Arzneimitteln GmbH, Vienna, Austria

#### INTRODUCTION

#### Introduction:

Factor VIII activity (FVIII:C) assays of samples containing recombinant FVIII or the new bispecific antibody emicizumab (Haemlibra®) can be associated with differences in FVIII recovery in vitro between one-stage-clotting-assays and chromogenic assays. Chromogenic assays designed with human proteins, offer the possibility to measure the activity and recovery of this new bispecific antibody emicizumab in patient samples. To monitor FVIII-INH titers with Nijmegen-Bethesda-Assays in haemophilic patients treated with emicuzumab, it was shown that only chromogenic assays with bovine proteins can be used.


**Aim** of this study was to investigate if chromogenic assay containing both, human and bovine proteins, can be used to measure the recovery of emicizumab in patient samples, and if the assay can be used in FVIII-INH determination by Nijmegen-Bethesda-Assay.

### MATERIALS AND METHODS


Plasma from Haemophilia-A patients was used for spiking with Refacto, Fanhdi and emicizumab. The FVIII activity was determined with one-stage-clotting-assay and TECHNOCHROM® FVIII:C, a chromogenic assay with human FIXa and bovine FX protein. Both assays were calibrated with reference plasma prepared from normal pooled plasma.

A set of lyophilized FVIII-INH positive controls containing either 25µg/mL or 75µg/mL emicizumab were tested with the FVIII INH reagent kit based on a modified Nijmegen-Bethesda-Assayprincipal. Sample were tested at 1:8, 1:16 and 1:32 dilutions respectively.

The TECHNOCHROM® FVIII:C chromogenic assay with human FIXa and bovine FX protein was used for determination of residual FVIII.



## RESULTS






Fig. 2a. b. c The sample spiked with increasing concentrations of Fanhdi showed a slope of 0.69 and  $R^2 = 0.9952$  for Fandhi. As expected the one-stage-clotting-assay underestimates Refacto AF in patient plasma, as shown by a slope of 0.4 and overesti-




Fig. 3 FVIII-INH titer of samples spiked with emicizumab were within ±10% of the unspiked value of respective sample.

Sample	Factor	BU/mL	Mean BU/mL	% Recovery
2K71B00	8	13.0	12.2	
2K71B00	16	11.3		
2K71B00+25µg/mL emicizumab	8	13.9	12.6	103.3
2K71B00+25µg/mL emicizumab	16	11.2		
2K71B00+75µg/mL emicizumab	8	13.6	12.4	101.6
2K71B00+75µg/mL emicizumab	16	11.2		
2K81B00	8	9.0	9.0	
2K81B00+25µg/mL emicizumab	8	8.1	8.1	90.3
2K81B00+75µg/mL emicizumab	8	8.6	8.6	96.5
2K82B00	16	19.7	16.7	
2K82B00	32	13.8		
2K82B00+25µg/mL emicizumab	16	17.3	17.3	103.3
2K82B00+75µg/mL emicizumab	16	17.8	16.3	07.6
2K82B00+75µg/mL emicizumab	32	14.9		97.6

Dilution

Tab. 1 Results obtained with FVIII INH reagent kit followed by chromogenic FVIII assay showed no significant sensitivity to emicizumab concentrations within the extherapeutic range, pected the recovery of FVIII-INH titer for all tested samples was 100±10%.

# CONCLUSIONS

Chromogenic assay with both human FIXa and bovine FX protein can be used for therapy monitoring of full length and truncated FVIII preparation, but is insensitive to emicizumab concentrations in therapeutic range. FVIII-INH titer in modified Nijmegen-Bethesda-Assay with chromogenic factor FVIII measurement is insensitive to emicizumab.

